CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder

International Journal of Urology

Volumn 20, Issue 2, 2013, Pages 251-255

  Choi, Jung Woo ^a   Kim, Younghye ^a   Lee, Ju Han ^a   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Bladder; CD74; Immunohistochemistry; Macrophage migration inhibitory factor receptor; Urothelial carcinoma

Indexed keywords

CD74 ANTIGEN; MILATUZUMAB;

ADULT; ADVANCED CANCER; AGE; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; BLADDER UROTHELIAL CARCINOMA; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA CELL; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STROMA CELL; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BIOPSY, NEEDLE; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84873270027     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03128.x     Document Type: Article

References (29)

1. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006; 27: 361-73.
2. Williams SG, Stein JP. Molecular pathways in bladder cancer. Urol. Res. 2004; 32: 373-85.
3. Falke J, Witjes JA. Contemporary management of low-risk bladder cancer. Nat. Rev. Urol. 2011; 8: 42-9.
4. Leng L, Metz CN, Fang Y etal. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 2003; 197: 1467-76.
5. Beswick EJ, Pinchuk IV, Minch K etal. The Helicobacter pylori urease B subunit binds to CD74 on gastric epithelial cells and induces NF-kappaB activation and interleukin-8 production. Infect. Immun. 2006; 74: 1148-55.
6. Beswick EJ, Bland DA, Suarez G, Barrera CA, Fan X, Reyes VE. Helicobacter pylori binds to CD74 on gastric epithelial cells and stimulates interleukin-8 production. Infect. Immun. 2005; 73: 2736-43.
7. Burton JD, Ely S, Reddy PK etal. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin. Cancer Res. 2004; 10: 6606-11.
8. Stein R, Qu Z, Cardillo TM etal. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004; 104: 3705-11.
9. McClelland M, Zhao L, Carskadon S, Arenberg D. Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am. J. Pathol. 2009; 174: 638-46.
10. Young AN, Amin MB, Moreno CS etal. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am. J. Pathol. 2001; 158: 1639-51.
11. Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl. Immunohistochem. Mol. Morphol. 2000; 8: 210-5.
12. Ishigami S, Natsugoe S, Tokuda K etal. Invariant chain expression in gastric cancer. Cancer Lett. 2001; 168: 87-91.
13. Kitange GJ, Carlson BL, Schroeder MA etal. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J. Neurooncol. 2010; 100: 177-86.
14. Borghese F, Clanchy FI. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin. Ther. Targets 2011; 15: 237-51.
15. Starlets D, Gore Y, Binsky I etal. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006; 107: 4807-16.
16. Becker-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Mol. Biol. Cell 2005; 16: 5061-9.
17. Lue H, Thiele M, Franz J etal. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007; 26: 5046-59.
18. Berkova Z, Tao RH, Samaniego F. Milatuzumab - a promising new immunotherapeutic agent. Expert Opin. Investig. Drugs 2010; 19: 141-9.
19. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARCPress, Lyon, 2004.
20. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC Cancer Staging Manual, 7th edn. Springer, Chicago, IL, 2010.
21. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 1994; 12: 259-93.
22. Gondo H, Narni F, Lee MS, Blick MB, Cabanillas F, Saunders GF. HLA class II antigen associated invariant chain gene expression in malignant lymphoma. Br. J. Haematol. 1987; 67: 413-7.
23. Sarker AB, Akagi T, Jeon HJ etal. Bauhinia purpurea - a new paraffin section marker for Reed-Sternberg cells of Hodgkin's disease. A comparison with Leu-M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber-H2 (CD30). Am. J. Pathol. 1992; 141: 19-23.
24. Jiang Z, Xu M, Savas L, LeClair P, Banner BF. Invariant chain expression in colon neoplasms. Virchows Arch. 1999; 435: 32-6.
25. Nagata S, Jin YF, Yoshizato K etal. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann. Surg. Oncol. 2009; 16: 2531-8.
26. Meyer-Siegler KL, Leifheit EC, Vera PL. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 2004; 4: 34.
27. Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J. Immunol. 1992; 149: 2391-6.
28. Roche PA, Cresswell P. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 1990; 345: 615-8.
29. Gold DV, Stein R, Burton J, Goldenberg DM. Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int. J. Clin. Exp. Pathol. 2010; 4: 1-12.